You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis

Article info

Article menu

Download PDFPDF

XML
Infectious diseases
Original research
Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis

Authors

  • Nomonde Ritta Mvelase Medical Microbiology, National Health Laboratory Service, Durban, South Africa Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa PubMed articlesGoogle scholar articles
  • Yusentha Balakrishna Biostatistics Unit, South African Medical Research Council, Durban, South Africa PubMed articlesGoogle scholar articles
  • Keeren Lutchminarain Medical Microbiology, National Health Laboratory Service, Durban, South Africa Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa PubMed articlesGoogle scholar articles
  • Koleka Mlisana Medical Microbiology, National Health Laboratory Service, Durban, South Africa Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Nomonde Ritta Mvelase; dlaminin15{at}ukzn.ac.za
View Full Text

Citation

Mvelase NR, Balakrishna Y, Lutchminarain K, et al
Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis
BMJ Open 2019;9:e031663. doi: 10.1136/bmjopen-2019-031663

Publication history

  • Received May 14, 2019
  • Revised October 8, 2019
  • Accepted October 11, 2019
  • First published November 6, 2019.
Online issue publication 
October 13, 2022
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.